Founded in 2018 and headquartered in Fremont, California, Alamar Biosciences is dedicated to developing cutting-edge technologies for the early detection and treatment of cancer and other diseases. Their core mission is to revolutionize healthcare by enabling the earliest possible diagnosis through advanced proteomics. Alamar offers products such as the NULISA™ Panels & Assays, which can profile thousands of protein biomarkers from a single fluid sample, and the ARGO™ HT System, which simplifies proteomics analysis.
Notable figures affiliated with Alamar Biosciences include key investors from their oversubscribed Series C financing round. The company has achieved significant milestones, including the launch of the NULISAseq CNS Disease Panel and NULISAqpcr pTau-Assays. Alamar's innovative technologies have set a new gold standard in protein detection, significantly impacting the field of early disease diagnosis and treatment.
